Crossmark

Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease

Crossref DOI link: https://doi.org/10.1186/s13195-018-0439-y

Published Online: 2018-11-03

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sánchez-Valle, Raquel http://orcid.org/0000-0001-7750-896X
Heslegrave, Amanda

Foiani, Martha S.

Bosch, Beatriz

Antonell, Anna

Balasa, Mircea

Lladó, Albert

Zetterberg, Henrik

Fox, Nick C.
Funding

Funding for this research was provided by:

Instituto de Salud Carlos III (PI160235)

the Leonard Wolfson Experimental Neurology Centre

Wellcome Trust Multi-User Equipment Grant

UK Dementia Research Institute

European Research Council
License Information

Text and Data Mining valid from 2018-11-03
More Information

Article History

Received: 9 February 2018

Accepted: 11 October 2018

First Online: 3 November 2018

Ethics approval and consent to participate

: The study was approved by the Hospital Clinic of Barcelona ethics committee (HCB/2012/7476) and all subjects gave written informed consent.

: Not applicable.

: HZ has served on advisory boards for Roche Diagnostics and Eli Lilly, has received travel support from Teva, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg, Sweden. NCF has received fees (paid to University College London) for consultancy from Eli Lilly, Novartis, Sanofi, Roche/Genentech, and GlaxoSmithKline, and for serving on a Data Monitoring Committee for Biogen. The remaining authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.